Semaglutide is a 31-amino-acid GLP-1 receptor agonist the foundation compound, characterised across the STEP obesity trials (0.25 2.4 mg weekly), the SUSTAIN type 2 diabetes programme (0.5 / 1.0 mg weekly), and SELECT (cardiovascular outcomes in obesity without diabetes)
When youre taking doses of compounded tirzepatide for weight loss, it starts to work within hours of the first time that you use a compounded tirzepatide injection
Trends in Analytical Chemistry, 29 (7), 578591
Gentle enough for daily use
The results showed that the study reached the primary and key secondary endpoints using the two measurement methods: compared with insulin glargine, at 52 weeks, all three doses (5mg, 10mg, 15mg) of tirzepatide significantly reduced blood glucose ( A1C) and body weight, and are statistically significant